

TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



Dr. Vinay Ch MD (Pathology & Chairman & Con				D (Pathology)	
NAME	: Mr. DIKSHANT				
AGE/ GENDER	: 30 YRS/MALE		PATIENT ID	: 1733328	
COLLECTED BY	:		REG. NO./LAB NO.	: 012501240002	
REFERRED BY	:		REGISTRATION DATE	: 24/Jan/2025 07:50 AM	
BARCODE NO.	: 01524328	COLLECTION DATE		: 24/Jan/2025 07:51AM	
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 24/Jan/2025 10:38AM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAI), AMBALA CANTT			
Test Name		Value	Unit	Biological Reference interval	
	CLIN	ICAL CHEMIS	TRY/BIOCHEMIST	'RY	
			OFILE : BASIC		
CHOLESTEROL TO	TAL: SERUM	195.06	mg/dL	OPTIMAL: < 200.0	
by CHOLESTEROL OXIDASE PAP		100100	ing, uz	BORDERLINE HIGH: 200.0 -	
				239.0 HIGH CHOLESTEROL: > OR =	
				240.0	
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		126.12	mg/dL	OPTIMAL: < 150.0	
				BORDERLINE HIGH: 150.0 - 199.0	
				HIGH: 200.0 - 499.0	
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION		50.02	mg/dI	VERY HIGH: > OR = 500.0 LOW HDL: < 30.0	
		59.92	mg/dL	BORDERLINE HIGH HDL: 30.0	
				60.0	
Ι DI CUOI ΕςΤΕΡΟΙ	· CEDIIM	109.92	mg/dL	HIGH HDL: > OR = 60.0 OPTIMAL: < 100.0	
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		109.92	iiig/ uL	ABOVE OPTIMAL: 100.0 - 129.0	
				BORDERLINE HIGH: 130.0 -	
				159.0 HIGH: 160.0 - 189.0	
				VERY HIGH: $> OR = 190.0$	
NON HDL CHOLES		135.14 ^H	mg/dL	OPTIMAL: < 130.0	
by CALCULATED, SPE	CIROPHOIOMEIRY			ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 -	
				189.0	
				HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0	
VLDL CHOLESTEROL: SERUM		25.22	mg/dL	0.00 - 45.00	
by CALCULATED, SPE	CTROPHOTOMETRY				
TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY		516.24	mg/dL	350.00 - 700.00	
CHOLESTEROL/HI	DL RATIO: SERUM	3.26	RATIO	LOW RISK: 3.30 - 4.40	
by CALCULATED, SPE	CTROPHOTOMETRY			AVERAGE RISK: 4.50 - 7.0	

KOS Diagnostic Lab (A Unit of KOS Healthcare)

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







	Dr. Vinay ChopraDr. Yugam ChopraMD (Pathology & Microbiology)MD (Pathology)Chairman & Consultant PathologistCEO & Consultant Pathologist						
NAME	: Mr. DIKSHANT						
AGE/ GENDER	: 30 YRS/MALE	PA	TIENT ID	: 1733328			
COLLECTED BY	:	RE	EG. NO./LAB NO.	: 012501240002			
REFERRED BY	:	RE	GISTRATION DATE	: 24/Jan/2025 07:50 AM			
BARCODE NO.	: 01524328	CO	LLECTION DATE	: 24/Jan/2025 07:51AM			
CLIENT CODE.	: KOS DIAGNOSTIC LAB	RE	PORTING DATE	: 24/Jan/2025 10:38AM			
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT						
Test Name		Value	Unit	Biological Reference interval			
LDL/HDL RATIO: SERUM by Calculated, spectrophotometry		1.83	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0			
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY		2.1 ^L	RATIO	3.00 - 5.00			

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com

